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Abstract
To achieve UNAIDS 90:90:90 targets at population-level, knowledge of HIV status must be followed by timely linkage to 
care, initiation and maintenance of antiretroviral therapy (ART) for all people living with HIV (PLHIV). Interpreting quan-
titative patterns using qualitative data, we investigate time taken to link to care and initiate ART amongst individuals aware 
of their HIV-status in high HIV-prevalence urban communities in the HPTN 071 (PopART) study, a community-randomised 
trial of a combination HIV prevention package, including universal testing and treatment, in 21 communities in Zambia and 
South Africa. Data are drawn from the seven intervention communities where immediate ART irrespective if CD4 count was 
offered from the trial-start in 2014. Median time from HIV-diagnosis to ART initiation reduced after 2 years of delivering 
the intervention from 10 to 6 months in both countries but varied by gender and community of residence. Social and health 
system realities impact decisions made by PLHIV about ART initiation.
Keywords HIV · Anti-retroviral treatment · Access · Linkage to care and ART  · Southern Africa
Background
The dual role of anti-retroviral treatment (ART) for HIV 
treatment and prevention is well established [1–3]. In 2014 
UNAIDS and partners set global HIV testing and ART 
coverage targets to drive policy makers towards enhancing 
access to treatment for all people living with HIV (PLHIV) 
[4]. This change followed the findings of two randomised 
trials, START [1] and TEMPRANO ANRS [5] demonstrat-
ing enhanced survival with immediate versus deferred ART. 
The individual and public health benefits of these findings 
are embedded in the 2015 World Health Organization and, 
subsequently, national ART guidelines [3, 6–9]. As a result, 
messaging around the role of ART for PLHIV has changed 
dramatically in the past 3 years, from ART only for those 
with CD4 counts below a certain threshold to a recommen-
dation of treatment, for all PLHIV irrespective of CD4 count 
[6, 9, 10].
Although mathematical models predicted that a public 
health approach of universal HIV testing with immediate 
ART treatment for all identified HIV-positive individuals has 
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the capacity to reduce HIV incidence [11], the population-
wide delivery of this strategy is challenging [12]. This is 
particularly so in high burden, resource-constrained settings 
[13–15] despite some recent encouraging results from com-
bination interventions [16, 17].
In this paper, we report findings on time taken to link to 
care from the HPTN 071 (PopART) study. This is a com-
munity randomised trial in 21 large, urban and peri-urban, 
resource-constrained communities with high HIV prevalence 
(20%) in Zambia and South Africa [18] with a total commu-
nity population of one million people. The trial is evaluating 
the effect of a combination HIV prevention package includ-
ing the Universal Test and Treat (UTT) strategy on popula-
tion level HIV incidence. The intervention was delivered to 
each household within a community by a cadre of trained 
lay-counsellors (Community HIV care Providers [CHiPs]). 
The CHiPs attempted to visit every household within a 
community on an annual basis (called a “Round”), for three 
complete Rounds, offering HIV education, HIV testing and 
linkage to care and treatment for HIV-positive individuals. 
In seven intervention (arm A) communities, from December 
2013 (prior to the implementation of changes in WHO and 
national ART guidelines in 2016) to December 2017, the 
PopART HIV prevention combination package included the 
offer of ART regardless of CD4 count to all PLHIV who 
knew their HIV-positive status.
For PLHIV, delays to treatment uptake have been docu-
mented in many different settings, including clinical trials. 
The HPTN 052 trial, undertaken at a time when ART ini-
tiation guidelines remained linked to a CD4 threshold, was 
designed to determine the effect of ART on the transmission 
of HIV from PLHIV to their HIV-negative sexual partners. 
The trial began in 2005, and was stopped early for efficacy, 
following an interim analysis in 2011. Of relevance to the 
focus of this paper, following the decision to stop the proto-
col early, all HIV-positive study participants randomised to 
the trial deferred treatment arm were offered ART, regard-
less of their CD4 count. One year later, despite counselling 
of participants and provision of access to ART, 17% had not 
taken up treatment and by 2015, on completion of the trial, 
4% remained off treatment [2]. This observation identified 
that although the participating PLHIV were well-informed 
and supported, some still needed and took time to start treat-
ment, reasoning that they were too healthy to start ART, 
their CD4 count was not low enough, and/or they feared 
drug side effects [2]. This evidence that some PLHIV needed 
time to start ART has been mirrored in several other studies 
[19–27]. The ANRS 12249 TasP trial [15] in KwaZulu-Natal 
(South Africa), despite high uptake of community HIV test-
ing, had challenges with linkage to care and ART initiation, 
showing that only 36.9% linked to care by 3 months after 
referral [28]. Some factors resulting in delayed uptake of 
ART are linked to broader health service delivery challenges 
that impede progress in providing treatment to everyone liv-
ing with HIV, including access to and availability of drugs 
[29–33]. The barriers to treatment associated with the health 
service may be compounded by, for example, the persis-
tence of HIV-related stigma which affects a person’s ability 
to access care and other demands on time due to making a 
livelihood or caring for children at home [34, 35].
We have previously reported the coverage of HIV testing 
[36] and ART [37], and estimates of the time from CHiP 
referral to linkage to HIV care and ART initiation during 
the first annual Round in the four Zambian arm A (inter-
vention) communities. Although we showed significant 
improvements in knowledge of HIV status and ART cover-
age by the end of Round 1 (the first year) of intervention, the 
median time from CHiP referral to ART initiation was much 
longer than had been anticipated, at ~ 10 months [37]. Sub-
sequently, towards the end of that annual Round 1 concerted 
efforts were made to facilitate more rapid linkage to care.
Following these efforts, we were able to estimate the 
time taken from CHiP referral to ART initiation during the 
second annual Round (the second year) of the intervention 
(June 2015–October 2016), across the four Arm A commu-
nities in Zambia and in addition the 3 Arm A communities 
in South Africa. In this paper we draw on these longitudi-
nal quantitative process data from Round 2, together with 
trial qualitative data, to address the question of why some 
PLHIV are less able or likely to start ART quickly even after 
1 year’s experience of delivering UTT, and in the context 
of support for linkage to care from CHiPs. Specifically, we 
describe intervention efforts to reduce the lag in linkage to 
care, present quantitative data on time to linkage to care and 
time to ART initiation, and through qualitative data provide 
the explanations given by PLHIV for the choices they have 
made about whether and when to link to HIV care and initi-
ate ART. Finally, we use the mixed methods evidence to 
reflect on current policy directions, particularly the strong 
global emphasis on commencing ART on the same day as 
first testing HIV-positive.
Methods
Setting
For the HPTN 071 (PopART) trial intervention, a commu-
nity was defined as the population catchment of a govern-
ment health care facility providing HIV services including 
ART. The seven communities included in this analysis were 
randomly allocated to receive the full PopART interven-
tion package, including offer of ART initiation regardless 
of CD4 count for PLHIV from the start of the trial, and 
prior to changes in guidelines. The communities included 
have a total population of ~ 200,000 in the four Zambian 
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communities, and ~ 100,000 in the three South African 
communities. The social context and HIV services in all the 
communities in both countries have been described else-
where [38]. An ancillary study on stigma was undertaken, 
which provides additional information on stigma experi-
ences in health facilities and levels of stigma in different 
communities, also described elsewhere [35, 39, 40].
The PopART intervention was a combination HIV pre-
vention package delivered by community HIV care provid-
ers (CHiPs) and is described in detail in Hayes et al. [18], 
and summarised here. CHiPs visited every household within 
a community annually offering HIV education and testing 
using routine point of care finger prick rapid testing [41] to 
all consenting household members. ART was provided by 
local government health care facilities. For all individuals 
newly-testing HIV-positive or reporting that they know they 
are HIV-positive but not yet on ART, the CHiPs through 
repeated household visits, encouraged and facilitated linkage 
to care for ART initiation at the local clinic. The ART drugs 
were provided through the routine health care system funded 
by PEPFAR-supported implementing partners. It should be 
noted that until the change in national guidelines in 2016 
(recommending prompt treatment, regardless of CD4 count), 
Arm A participants had to sign a consent form if their CD4 
count was > 500, prior to initiation of ART. Because they 
had to wait for their CD4 count results, there was a brief 
delay of approximately 2 weeks between linkage to care and 
ART start.
In Round 2, several new strategies were put in place to 
encourage linkage to care, to be undertaken by the CHiPs, 
and existing practices from Round 1 were reinforced [42]. 
These included assisted referrals: CHiPs escorting clients 
to the clinic to help them link to care and specially trained 
counsellors in each community to assist with linkage; work-
ing with existing community health care workers to track 
clients; following up with clients who missed clinic appoint-
ments and holding meetings with local clinic staff on a regu-
lar standardised basis to review which CHiP clients had, or 
had not, linked to care and/or started ART.
Quantitative Data
In order to offer annual HIV testing as well as other HIV 
prevention services, CHiPs aimed to contact all individu-
als (aged ≥ 15 years) at least once every round to offer 
participation in the intervention. All household members 
were asked for verbal informed consent to take part in the 
intervention and permission to collect data electronically. 
Individuals provided written consent for HIV counselling 
and testing. CHiPs recorded basic data on the household and 
more detailed information for individuals who consented 
to participate in the intervention. Data captured electroni-
cally included age and gender, self-reported HIV status, the 
outcome of HIV testing by CHiPs, self-reported informa-
tion on HIV care registration and current (during the last 
1 month) ART use, and whether a referral to HIV care was 
given. Analysis was restricted to participants aged 15 years 
and older, although HIV testing was offered irrespective of 
age.
Individuals were “known HIV-positive” to the CHiPs in 
Round 2 if they participated in Round 2 and either (i) had 
self-reported or tested HIV-positive in Round 1, and verbally 
confirmed their HIV-positive status in Round 2 (ii) self-
reported HIV-positive for the first time in Round 2, or (iii) 
tested HIV-positive with CHIPs in Round 2. For individuals 
who self-reported they had previously registered for HIV 
care, CHIPs asked to see the patient ART card, and if the 
card was provided then the ART card number was recorded.
For all individuals known to be HIV-positive by the defi-
nition above, CHIPs undertook follow-up visits to support 
linkage to care and subsequent ART initiation, as well as 
to collect self-reported information on whether and when 
these outcomes were achieved. If the individual was not at 
home at the time of the CHiP follow-up visit, then the CHiP 
recorded that they had made a visit but were not able to meet 
the individual.
Analyses of the time from CHiP referral to linkage to 
care, from CHIP referral to ART initiation, and the time 
from linkage to care to ART initiation, were done using the 
Kaplan–Meier “time-to-event” method. We used Cox regres-
sion for analysis of whether these times differed by country, 
community, gender or age group. We used follow-up data 
to 30th September 2017 and for individuals who were not 
known to have started ART by this date, we censored their 
follow-up on the last date on which they met the CHiP in 
person. Individuals do not contribute to the analysis if they 
were never followed up in person after they were referred 
to care.
Qualitative Data
Social science enquiry encompassed qualitative research 
prior to the intervention period (2012–13) and during the 
intervention. The trial qualitative research used ethno-
graphic and participatory research methods [43] and was 
designed to first document rapidly key features of study 
communities of relevance to HIV prior to the intervention 
period through broad brush surveys (BBS) [44], and then, 
during the intervention, focus on community responses, 
implementation and different trajectories around a range 
of HIV outcomes and decisions (labelled ‘qualitative 
cohort’). In this paper, we draw on findings on community 
characteristics from the BBS (the methods are described in 
detail in other papers, see [43, 44]) and on findings from 
a sub-sample of PLHIV in the qualitative cohort in both 
countries documenting the challenges in linkage to care 
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alongside other experiences. The research was carried out 
by a core team of Zambian and South African men and 
women social scientists trained in qualitative data collec-
tion methods, who were competent in the appropriate local 
languages. In both countries, individual social scientists 
were allocated to three to four communities where they, 
and a field research assistant, conducted all research com-
ponents as a pair, building their familiarity with particular 
communities and families over time. Efforts were made 
to have each pair composed of a man and a woman where 
possible.
The aim of the qualitative cohort research was to recruit 
participants purposively sampled to represent different 
HIV-related decisions and outcomes across different trial 
arms, geographical locations, age, gender, and key popula-
tions. Sixty-eight households (21 in Zambia and 47 in South 
Africa) where PLHIV resided were recruited from March 
2016 to November 2017 (a time period which overlapped 
with the quantitative data collection in Rounds 2 and 3). 
Two-thirds of the PLHIV in the households included in the 
cohort were on ART. Of the other third, half had defaulted 
from treatment and half were yet to start ART. Participants 
in the cohort were interviewed at least three times, and 
households visited at least six times over a year. The inter-
viewers asked about family, kin and social networks, move-
ment within and outside of the household and community, 
household livelihood, HIV and general health service access, 
sex, love and romance, and future ambitions and fears. Inter-
views were recorded, and notes were also taken during and 
after interviews, with each social scientist first writing up a 
reflective summary of the findings and then debriefing with 
other team members, before translating and transcribing the 
interviews. ATLAS-ti qualitative analysis software was used 
to manage the data.
This body of data was closely reviewed and analysed by 
the social science team for this paper, focusing on the partic-
ipants who were living with HIV from across all seven Arm 
A communities with the aim of explaining time between 
HIV diagnosis and ART initiation. Notes from field work, 
summaries, debriefing sessions and transcriptions were 
scrutinised. This was done by first holding two-day analysis 
workshops in both countries with the social scientists who 
carried out the fieldwork. This process allowed key themes 
to emerge across both countries (for example, `gender pat-
terns and differences’, `when it makes sense to start ART 
on the same day’), which were then shared to arrive at a 
shared set of codes. The teams were asked to review the 
data to code against the themes, ensuring that coding was 
cross checked for consistency across coders throughout the 
process. Each country produced a synopsis document, which 
was discussed by the country teams highlighting differences 
and similarities, to arrive at the list of themes (shown in 
Tables 3 and 4) used in this paper.
Ethical Considerations
The HPTN 071 (PopART) study was approved by the Lon-
don School of Hygiene and Tropical Medicine, University 
of Zambia, and Stellenbosch University (N12/11/074), eth-
ics committees and by other health governmental authori-
ties. Research participants signed written informed con-
sent. Those who consented to a finger prick rapid test 
signed written consent according to standard government 
guidelines. Data from the CHiP intervention were col-
lected following verbal consent.
To ensure confidentially, quotations from the qualitative 
data are only labelled with Z = Zambia and SA = South 
Africa, and community number.
Results
Quantitative Findings
During Round 2, in Zambia 3435 and in South Africa 
1262 HIV-positive individuals were referred to HIV care 
by CHiPs, among those who were not on ART on the date 
of first participation in Round 2. Overall, the estimated 
median time from CHIP referral to ART initiation was 
~ 6 months in Round 2 in both Zambia and South Africa, 
considerably less than the median of ~ 10 months in both 
countries in Round 1 but still slower than had been tar-
geted at the start of the intervention (Fig. 1a; the horizon-
tal red line is drawn at 50% to correspond to the median 
time to ART initiation).
Time from CHiP Referral to ART Initiation—Overall 
Estimates
Overall, we estimated that 39, 50, and 67% initiated ART by 
3, 6, and 12 months respectively after first referral to care by 
CHiPs in Round 2 in Zambia (Fig. 1b), with corresponding 
(and slightly lower) estimates of 36, 47, and 66% in South 
Africa (Fig. 1b).
Time from CHiP Referral to Linkage to Care 
(Attendance at Clinic)—Overall Estimates
The estimates for the percentage who were linked to care, 
i.e. first attended a clinic, by 3, 6 and 12 months was 45, 57 
and 71% respectively after first referral to care in Zambia, 
and 48, 60, and 79% in South Africa (Fig. 1c); these esti-
mates indicated slightly more rapid linkage to care in South 
Africa compared with Zambia.
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Time from Linkage to Care (Attendance at Clinic) 
to ART Initiation
Notwithstanding the imprecision around our estimates of 
both the date of linkage to care and the date of ART initia-
tion, because both dates were based on self-reported infor-
mation, we also estimated the time from linkage to care to 
ART initiation among individuals who linked to care. We 
estimated that 78, 90, and 94% started ART by 1, 3, and 
6 months respectively after linkage to care in Zambia, with 
corresponding (and slightly lower) estimates of 64, 81, and 
87% in South Africa (Fig. 1d).
Time from Linkage to Care (Attendance at Clinic) 
to ART Initiation, Relative to Time from CHiP 
Referral to Linkage to Care
Overall, for most individuals the time from linkage to care to 
ART initiation was short, with a median of less than 1 month 
(Fig. 1d), while the time from referral to linkage to care was 
longer, with a median of 4 months in Zambia and 3.5 months 
in South Africa (Fig. 1c).
Time from CHiP Referral to ART Initiation—Patterns 
by Gender, Community, and Age Group
Patterns by gender, community and age group for the time 
from CHiP referral to ART initiation were similar to those 
for the time from CHiP referral to linkage to care (attend-
ance at clinic). Here we have summarized the patterns for 
our estimates of time to ART initiation (Tables 1 and 2), 
with estimates for time from CHiP referral to linkage to care 
provided in Supplementary Table 1.
For Zambia, findings are summarised in Table 1 and 
Fig.  2. The median time to ART initiation was longer 
for women than men (6.6 and 4.4 months respectively, 
p < 0.001). There was strong evidence of differences 
between communities (p < 0.001), with the median time to 
Fig. 1  Time from CHiP referral to ART initiation, time from CHiP referral to linkage to HIV care, and time from linkage to HIV care to ART 
initiation
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ART initiation being similar in communities 2 and 3 (5.7 
and 5.6 months respectively) but shorter in community 
1 (1.8 months) and longer in community 4 (9.5 months). 
Among men, it was longest for those aged 20–24 years, and 
among women it was longest for those aged ≥ 55 years.
For South Africa, findings are summarised in Table 2 
and Fig. 3. The median time to ART initiation was shorter 
for women than men (6.0 and 9.1 months respectively, 
p = 0.006). There was strong evidence of differences among 
communities (p = 0.007) with the median time to ART 
initiation being 5.6, 7.9, and 3.9 in communities 1, 2 and 
3 respectively. Among men, it was shorter for older men 
aged ≥ 45 years compared with those aged 25–29 years, and 
longer for women aged 15–19 years compared to those aged 
25–29 years.
Time from Linkage to Care (attendance at clinic) 
to ART Initiation—Patterns by Gender, Community, 
and Age Group
The estimated time from linkage to care to ART initiation 
was similar for men and women, and across communities, 
Table 1  Time to initiate ART after first CHiP referral to HIV care in Round 2—Zambia
Hazard ratios and their 95% CI, and estimates of the percentage of individuals with the outcome by key time points, are shown in bold
a Estimated from “time to event” analysis
b For overall comparison of women with men, adjusted hazard ratios are obtained from a multivariable Cox regression model including commu-
nity, age group, and gender; for overall comparison among communities, adjusted hazard ratios are obtained from a multivariable Cox regression 
model including community, gender, and gender-specific hazard ratios for age group; for comparison across age groups, adjusted hazard ratios 
are obtained from gender-specific multivariable Cox regression models including community and age group; age-specific estimates are presented 
separately for men and women because there was statistical evidence the age pattern was different for men and women (p = 0.004)
c Number who either started ART within 1 month after referral or have a follow-up visit ≥ 1 month after referral, and similarly for other time 
points (3, 6, 12 months after referral)
d p-values are from Cox regression, from likelihood ratio tests of whether there is evidence of association between an individual characteristic 
(e.g. gender, or the community in which an individual lives) and the outcome of “time to ART initiation”
e / = Cannot be estimated, because no one followed up to this time point
Number 
referred to HIV 
care
ART initiated (%)a Hazard ratio, 
unadjusted
Hazard ratio, 
 adjustedb
95% CI
1 month 3 months 6 months 12 months
Overall 3435 23
95% CI 21–24
(n = 2570)c
39
95% CI 37–41
(n = 2347)
50
95% CI 48–52
(n = 2188)
67
95% CI 65–69
(n = 1973)
Gender
 Men 1117 26 44 56 71 1 (ref) 1 (ref) p < 0.001d
 Women 2318 21 37 48 65 0.82 0.82 0.73–0.91
Community
 1 256 39 54 65 78 1.52 1.55 1.29–1.87
 2 856 21 39 51 67 0.95 0.94 0.83–1.07
 3 1775 24 40 52 69 1 (ref) 1 (ref) p < 0.001
 4 548 14 26 38 56 0.67 0.68 0.58–0.79
Men, age group (years)
 15–19 29 33 39 63 69 1.01 0.95 0.54–1.67
 20–24 100 17 31 46 59 0.70 0.72 0.50–1.03
 25–34 453 29 46 54 67 1 (ref) 1 (ref) p = 0.04
 35–44 369 25 43 57 74 1.03 1.06 0.86–1.31
 45–54 132 25 47 58 79 1.17 1.18 0.90–1.55
 55 + 34 26 71 79 /e 1.71 1.75 1.11–2.75
Women, age group (years)
 15–19 152 23 40 53 74 1.17 1.10 0.84–1.43
 20–24 556 19 37 48 67 1.03 1.03 0.88–1.21
 25–34 968 21 36 47 65 1 (ref) 1 (ref) p = 0.24
 35–44 428 22 37 51 66 1.03 1.04 0.88–1.23
 45–54 154 26 37 45 58 0.90 0.89 0.70–1.15
 55 + 60 19 29 35 51 0.67 0.66 0.44–0.99
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in Zambia. In South Africa there was evidence that this time 
was shorter in communities 1 and 3 compared with com-
munity 2, but the difference was relatively small (shown in 
Supplementary Table 2). In both countries, for both men and 
women there was no evidence of differences by age group 
(data not shown).
Qualitative Findings
Our findings show that there are differences in time to ART 
initiation between communities and these can be catego-
rised by: distance between household and clinic; levels of 
socio-economic status and employment; reported clinic staff 
workload at the health care facility; and the fear of being 
seen accessing services affecting time to ART initiation.
For example, the health facility in Community 1, is 
located quite far from the town centre, the population the 
facility serves is relatively educated, middle-class with some 
PLHIV working within the area. This one ART clinic is 
not particularly congested (according to users), because of a 
lower overall population density compared to other commu-
nities. In contrast, in Community 4, the health care facility 
is located close to the town centre. The population access-
ing care there are mostly of lower socio-economic class, 
Table 2  Time to initiate ART after first CHiP referral to HIV care in Round 2—South Africa
Hazard ratios and their 95% CI, and estimates of the percentage of individuals with the outcome by key time points, are shown in bold
a Estimated from “time to event” analysis
b For overall comparison of women with men, adjusted hazard ratios are obtained from a multivariable Cox regression model including commu-
nity, age group, and gender; for overall comparison among communities, adjusted hazard ratios are obtained from a multivariable Cox regression 
model including community, gender, and gender-specific hazard ratios for age group; for comparison across age groups, adjusted hazard ratios 
are obtained from gender-specific multivariable Cox regression models including community and age group; age-specific estimates are presented 
separately for men and women because there was weak statistical evidence the age pattern was different for men and women (p = 0.06)
c Number who either started ART within 1 month after referral or have a follow-up visit ≥ 1 month after referral, and similarly for other time 
points (3, 6, 12 months after referral)
d p-values are from Cox regression, from likelihood ratio tests of whether there is evidence of association between an individual characteristic 
(e.g. gender, or the community in which an individual lives) and the outcome of “time to ART initiation”
e / = Cannot be estimated, because no one followed up to this time point
Number 
referred to HIV 
care
ART initiated (%)a Hazard ratio, 
unadjusted
Hazard 
ratio, 
 adjustedb
95% CI
1 month 3 months 6 months 12 months
Overall 1262 18
95% CI 15–20
(n = 855)c
36
95% CI 33–40
(n = 788)
47
95% CI 44–51
(n = 723)
66
95% CI 63–70
(n = 644)
Gender
 Men 436 16 31 42 58 1 (ref) 1 (ref) p = 0.006d
 Women 826 19 39 50 71 1.33 1.32 1.08–1.61
Community
 Community 1 204 25 37 53 72 1.30 1.23 0.96–1.57
 Community 2 909 14 34 45 63 1 (ref) 1 (ref) p = 0.007
 Community 3 149 31 49 56 76 1.54 1.48 1.15–1.90
Men, age group (years)
 15–19 5 33 67 /e / 4.70 4.85 1.51–15.61
 20–24 44 18 26 40 47 0.91 0.88 0.46–1.67
 25–34 195 14 25 35 56 1 (ref) 1 (ref) p = 0.04
 35–44 135 12 33 43 57 1.10 1.02 0.69–1.52
 45–54 48 30 44 62 70 1.76 1.60 1.00–2.57
 55 + 9 14 57 57 / 3.01 2.51 1.07–5.92
Women, age group (years)
 15–19 48 6 28 36 48 0.59 0.58 0.32–1.05
 20–24 188 19 35 45 75 0.97 0.98 0.75–1.29
 25–34 369 17 41 51 70 1 (ref) 1 (ref) p = 0.42
 35–44 149 24 42 54 70 1.03 1.01 0.75–1.36
 45–54 54 23 37 54 76 1.08 1.03 0.70–1.53
 55 + 18 25 57 71 71 1.40 1.41 0.66–3.01
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engaged in the informal economy and often involved in 
mobile livelihoods (for example: cross country-border trade 
and fishing). Women traders in this community work long 
days in markets or selling by the roadside and are involved in 
trade which also involves periods away from the community, 
restricting their opportunities to attend the clinic. Alcohol 
use is reported to be high in this community. The clinic is 
congested (waiting time was usually > 3 h).
Similarly, in South Africa there is an observed associa-
tion between clinic burden (those serving over 1000 clients 
a month are considered over-burdened), and a slower time to 
ART initiation. Community 3, where there is a shorter aver-
age time to start ART, is a relatively small community with 
lower HIV prevalence and fewer people initiating ART each 
month. In contrast, community 2 is a relatively large ‘gate-
way’ community for people entering Cape Town from East-
ern Cape searching for employment opportunities and has a 
relatively high HIV prevalence, and the clinic is busy. Even 
before the HPTN 071 (PopART) trial began the clinic had 
a much larger number of clients on ART than the other two 
communities. Thus, it is notable that in both countries, the 
populations slowest to initiate ART are those with transient 
populations (engaged in mobile livelihoods) and congested 
health facilities.
Health system, structural and social reasons for taking 
time to link to care are summarised in Table 3 (below). We 
have grouped the summary findings in the table by health 
care facility, community, household and individual factors, 
although several reasons listed are cross-cutting. We now 
elaborate on some of the reasons given for delaying treat-
ment listed in Table 3, including the gender and age factors 
apparent in the process data, using italics to highlight rea-
sons mentioned in the table, to ease cross-referencing.
Health Service Factors
The fear of being seen at a clinic accessing services, includ-
ing starting and collecting ART, was a deterrent mentioned 
by participants in both countries in all seven communi-
ties. The stigma associated with accessing HIV-treatment 
Fig. 2  Time from CHiP referral to ART initiation in Zambia in Round 2, by gender, community, and age group
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services included the anticipated stigma of people in the 
community finding out about clinic attendance. For example, 
one couple in South Africa complained that being familiar 
with health staff at the local clinic stopped them from initi-
ating treatment because they feared the resident health staff 
would disclose their status to others. Others were concerned 
about being seen by neighbours and friends waiting in parts 
of the clinic associated with HIV care.
Other factors given for not linking to care included confu-
sion over changing and seemingly-conflicting messages from 
health workers about when to start ART because of shifting 
guidelines. Others had been advised by health workers to 
eat nutritious food with their treatment which they could 
not afford: a 47-year old woman LHIV in Zambia recalled 
how health workers told her to buy fruits, but she and her 
husband could not always pay rent for the room they lived 
in, so could not spend more money on food. As a result, they 
had not linked to care.
There were worries about the stigma of being seen 
once on treatment. A Zambian older man (Z10) recounted, 
“some people fear queuing at the clinic to collect drugs”. 
He attributed congestion and lack of privacy in health facili-
ties as contributing to making accessing drugs ‘public’, and 
remarked, “Accessing drugs should be private or the gov-
ernment should find another way of providing HIV drugs”. 
In Zambia, respondents accessing care in the busy health 
facilities spoke about long waiting times (over 3 h), with 
staff and clients sometimes being rude to each other. A few 
respondents expressed concern that there was preferential 
treatment for some clients and some who used their author-
ity and status to go ahead in the queue.
One woman in South Africa (S16) talked about the dis-
comfort she felt about her nearby health care facility, a factor 
which contributed to other reasons she gave for not starting 
ART.
The clinic staff like to gossip, I mean, I don’t feel 
comfortable with them…. I would probably take 
ART somewhere else, these people from here are not 
right…. They know me and they like gossiping out-
side.
Fig. 3  Time from CHiP referral to ART initiation in South Africa in Round 2, by gender, community, and age group
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Table 3  Reasons not to start ART quickly in seven communities (four Zambia, three South Africa)
Reasons
Health services factors Congestion
Long waiting times (> 3 h) affecting livelihood demands
Clinic staff perceived to open clinic on time but start work late
Frustration with having to be at the clinic early in the morning to avoid long queues
Nursing staff perceived to take extended tea breaks and lunch (South Africa)a
The risk of ‘being seen’
PLWH anticipated being seen by others who knew them at the clinic
Fear of involuntary disclosure when accessing services in designated areas of HIV care
HIV services in facilities also considered to offer privacy once in designated areas
Quality of HIV testing/ART 
Some rumours about false positives
Some lack of trust in the accuracy of HIV test results
Some (limited) rumours about variation in the quality of the ART (in areas with predominantly black community mem-
bers thought to receive ‘weaker’ ART) (South Africa)
Some rumours of clinic staff perceived to be reimbursed for each HIV-positive diagnosis (South Africa)
Record-keeping
Lost clinic folders/CD4 results at facilities
Locating files increased waiting time
Frustration with misplaced files making PLWH leave before collecting the drugs
HIV service delivery structures/processes
ART initiation procedures lengthy (re-testing for HIV & counselling) and unclear (Zambia)
Clinic operating hours limited (ART services provided in the week day morning) (Zambia)
Lack of laboratory reagents/apparatus for necessary tests prior to ART initiation delays start of treatment. (Zambia)
Requirement to provide identification or proof or residence problematic for people living in informal housing structures 
with no formal physical addresses (South Africa)
Anticipated difficulties of re-engaging with HIV services
Anticipation of being admonished by health care workers for missing treatment/defaulting
Worry about adhering to appointment dates alongside competing alternative responsibilities (livelihood, family respon-
sibility)
Informal charges
Informal costs to access care: missing work/loss of income, travel cost to clinic
Offering informal incentives (money) to both professional and lay health care workers a strategy of getting around con-
gestion/avoiding queuing (Zambia)
Health worker attitudes
Some negative remarks made by health care workers when providing services
Some unsatisfactory health care worker and client relationships
Preferential treatment to some clients
Community Factors Gender
More women accessing HIV services than men (linked to antenatal care access)
Men considered busy and difficult to link to care
Community Health Worker relationships
Community health workers resident in the community, so some fears of confidentiality breaches
Some tensions between lay workers and clinic staff (South Africa)
Alternative treatment options
Faith healing—belief that HIV can be cured through prayer (Zambia)
Herbal remedies and immune boosters used to improve health
Traditional medicine is taken as supportive care (South Africa)
Some participants use drugs (‘tik’ [crystal meth], marijuana) to self-medicate or as a form of escapism, which can delay 
treatment access (South Africa)
Other priorities/concerns/illnesses
Competing concerns such as: securing income, substance abuse, drug use
Other health conditions (e.g. TB, diabetes)
Crime (often dangerous/violent) poses challenges (South Africa)
Some reports of theft of anti-retroviral drugs for recreational drug use (South Africa)
Isolation due to fear of disclosure to other community members
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Health worker attitudes were mentioned by others with 
some fearing being reprimanded by health care workers 
for failing to take treatment. Stories of people who had 
been scolded at the health care facility for not adhering 
to treatment when they tried to access care after a gap in 
treatment, were recounted by people in both countries. 
These were all factors which made access difficult once 
someone had linked to care, and deterred others who were 
yet to start ART.
While health system factors deterred some PLHIV from 
accessing treatment, family and community views also 
influenced uptake, often in association with the stigma-
tising attitudes in the community about those accessing 
HIV-care services.
Table 3  (continued)
Reasons
Household Factors Food
Food insecurity affecting uptake of ART (perception that when taking a strong drug like ART one needs to take it with 
food and stick to a special diet)
Household survival factors contribute delays in accessing treatment (food availability depends on tenuous and variable 
income)
Livelihood
Employment scarce and some people hesitant to miss work in order to attend the clinic
Labour migration potentially impacts the decision to link to care
Age
Adolescents needing guardian’s consent to start ART 
Lay workers delaying disclosure of HIV status to adolescents in the absence of guardians (Zambia)
Partner support/couple and gender dynamics
Difference in opinions among couples on whether to start ART or not
Anticipated negative reaction to women’s treatment initiation (threats of divorce, violence, abuse, lack of support, dis-
closure to wider community) can contribute to delays in treatment access
Women’s dependence on husbands affecting own decision-making capacity especially in Zambia
Individual Factors Waiting to be sick/feeling fine/managing without
Current state of ‘feeling well’ seen as motivation not to take medication yet
Conflict with earlier messaging from health facilities that one needed to ‘be sick’ (have low CD 4 levels) to be able to 
access treatment
Taking care of self through appropriate diet and use of herbal remedies without feeling sick gives indication of manag-
ing without ART 
Influence from other PLWH who have not taken ART despite living with HIV for many years
Some perceptions that medical staff will not be serious about treatment if clients do not present as ‘sick’ (South Africa)
Acceptance/readiness/denial
Non-acceptance of HIV status affects linkage to care
Needing more time to accept HIV status after HIV diagnosis
Not being ready to commit to lifelong treatment
Some health care workers felt it was right to give time to PLWH to accept their status and be ready to take up treatment
Gender
Intimate partner violence: some women fear accessing treatment because of partner’s attitude and behaviour
Men and women of different ages respond to offers of testing and treatment differently
Marginal identity
Transient people (fisherfolk, traders, seasonal farm workers) face challenges in accessing care
Sex workers, MSM, transgender individuals express fear of anticipated stigma at facilities (from community and some 
health staff) (South Africa)
Substance use
Alcohol use/abuse affects decisions to link to care and adhere to treatment
Alcohol seen as competing with ART treatment regimens—‘choose’ between substances and treatment because belief 
cannot use substances and be on treatment
Impact of ART on body & for life
Fears of implications for life-long commitment to medication
Pill burden seen as potentially overwhelming (often based on knowledge of number of pills taken by PLHIV in the past)
Some PLWH expressed needing to take treatment ‘breaks’ but discouraged to do so by facility staff
a Where a reason was given in one country, this is marked with the country name
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Community and Household Factors
In both countries people were often juggling their livelihood 
needs with starting ART, fearing time lost accessing care 
when they needed to work [45]. Some PLHIV who were the 
main breadwinners and had not started ART, would rather 
use their strength to earn an income and continue providing 
for their family, while they were feeling healthy, than go for 
treatment. Sometimes making a living involved long days 
in the market or months away in fishing camps, farming, 
mining or the road and construction camps.
A woman sex worker living with HIV and not yet on 
ART in South Africa (S14) commented that she had to use 
her time to look for clients, and that having no clients meant 
she earned no money and there would therefore be no food at 
home. When she was pregnant she used antiretroviral drugs 
for the prevention of mother to child transmission of HIV 
(PMTCT), because her partner used to support her then, so 
that she did not infect the unborn baby. However, she did not 
continue with ART after PMTCT. She said she has not been 
sick ever since she found out about her status so did not see 
the need for treatment.
Poverty and lack of food influenced the decision of some 
people to delay treatment uptake, as mentioned above. A 
41-year-old woman in South Africa (S14) commented:
So, you have to take treatment every day. So, can you 
take treatment on an empty stomach? Really? Because 
even if you are working, there is this maybe two weeks 
before payday you don’t have anything to eat. So, 
you’ll have to take a glass of water and pills and go to 
bed without anything you see. That’s why HIV people, 
most of the cases, they just default and go drinking 
[alcohol].
Maturity and age engendered responsibility and autonomy in 
both women and men, sometimes, but not always, making it 
easier for older people to decide to start ART. The responsi-
bility of being a provider prompted one 48-year-old Zambian 
man (Z10) to take treatment; “if I take treatment, I will be 
able to look after my family. If I do not take the treatment it 
is the family that will suffer”.
Disclosure of HIV status to partners, between women to 
their male spouses (in Zambia) was cited as a reason to delay 
attending care and starting ART. One strategy was to hold off 
disclosing an HIV-positive status to a partner until they also 
tested for HIV. In Zambia, women were more likely to be 
married and living with their husbands than in South Africa. 
Sometimes, it was up to men in the household to decide 
if women should start ART or not. Many Zambian women 
participants spoke of experiencing gender-based violence 
(physical and verbal), because of the stigma of HIV-infec-
tion and assumptions on the part of the male partner about 
the woman’s sexual behaviour or the woman’s accusations 
against the man and his behaviour that could have resulted in 
her infection. Thus, women in Zambia appeared constrained 
by male hegemony. This was reflected by a younger woman 
on ART (Z2) who talked about women in her community 
being beaten and insulted by their husbands for question-
ing the man’s behaviour, and then hiding indoors for fear of 
people seeing their physical injuries. Another woman who 
was HIV-negative (Z7) relayed how violence and the threat 
of violence can affect a woman’s decision to take treatment:
a man beat up his wife because she started ART, 
although even he tested HIV-positive. He is one of 
the people who says ‘HIV and its treatment is a lie, 
they just cheat us about these drugs’. So right now the 
woman is sick, she is bedridden.
Although fewer women in our study population were mar-
ried in South Africa than in Zambia, amongst those who 
were, participants said it was harder for a woman to start 
treatment if her husband had not begun ART. A 21-year-old 
women living with HIV whose husband was in prison said:
I disclosed my status to my in-laws, they advised that I 
wait for my husband to come out of jail before I could 
start ART. I will wait for him to be released from 
prison to get permission to start ART. If he refuses, 
then I won’t start.
In both countries, gender was an important factor in treat-
ment access. Women had more frequent contact with the 
health facility than men through pregnancy and child health 
needs, and the health facility was seen more as women’s 
space. However, whereas young men’s freedom to move 
around the community and engage in informal livelihood 
activities sanctioned and facilitated their use of the clinic 
in Zambia, in South Africa, men were more likely to resist 
going to the clinic. A South African man living with HIV 
(S21) was initiated onto ART but quickly stopped taking 
it. He was a gang member and an active drug user (tak-
ing Mandrax [methaqualone] and Tik [crystal meth]), he 
had recently been in prison and continued to be involved in 
criminal activities. As in this example, past-history, gang 
culture, alcohol and drugs were said by participants to mean 
that men did not prioritise their health, as also shown in find-
ings from other research [34, 46, 47].
Individual Factors
Despite community engagement and messaging on the ben-
efits of immediate ART, many people had internalised previ-
ous health messaging about treatment being appropriate only 
for those who were sick, and were cautious about accepting 
the change in advice [38]. Therefore, some considered imme-
diate treatment appropriate for those who are ill, pregnant 
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or in a discordant relationship. A Zambian 51-year-old man 
(Z7) explained: “
When I tested HIV-positive I did not see it fit to start 
ART because I was not feeling sick, I did not have any 
pain and I did not feel weak because I used to even 
lift heavy weights. So, I felt that even if I start taking 
treatment, it will not change anything.
For other PLHIV, although understanding the health ben-
efits of antiretroviral treatment and expressing gratefulness 
for wider ART access, people talked of the time needed to 
‘accept’ the diagnosis, to contemplate disclosure, house-
hold living and clinic options, and to consider the impact of 
treatment on the body, livelihood and relationships. People 
often talked about the need to `process’ the information that 
they were HIV-positive. A 21-year-old man (S13) who tested 
HIV-positive with one of the CHiPs teams in April 2017, 
said that when he heard he was HIV-positive “I couldn’t 
believe it”. He was previously HIV-negative in October 2016 
and his disbelief prevented him from accessing care. He also 
said he was kept busy with other things which kept him from 
the clinic.
While some respondents talked about the fear of starting 
ART, they did not always indicate concern that ART would 
itself have an adverse impact on their bodies. Instead, con-
cern often focused on the worries of being forced to interrupt 
ART due to drug stock-outs, a situation beyond their control.
Denial, anger, sadness, and questioning were common 
responses amongst adolescents living with HIV when they 
learnt of their status. One 21-year-old perinatally-infected 
man (Z2), who had stopped taking ART, said that he ‘did 
not believe in ART’. A 22-year-old woman living with HIV 
(Z8) shared her experience when she first found out she was 
HIV-positive:
I felt bad, I cried I won’t lie. I cried because I wasn’t 
expecting [it], I had a lot of thoughts that came that 
I should kill myself and do other things, […] then I 
thought about home where I stay, how they were going 
to receive me looking at how I am living…
For younger people, it was said to be harder to accept your 
status. A woman in South Africa (S18) mentioned that 
young people feel they are too young to be taking treatment 
for the rest of their life and they do not have the discipline 
to be taking ART every day. Another Zambian 17-year-old 
girl living with HIV (Z7) said when she first found out she 
had HIV:
I felt very bad, whereby many questions came to my 
head like, was I born to be an ARV taker or maybe 
to be addicted because my life relies on these same 
ARVs. It was very hard for me.
Reasons to Start Treatment Promptly
Yet, despite the many reasons given for delaying starting 
care, participants in both countries did recognise the impor-
tance of starting treatment straightaway, at least for some 
people. These reasons, summarised in Table 4, point to the 
value placed on health care facility access and the impor-
tance of the support of family and friends as well as being 
well enough to make a living to contribute to the family.
Table 4  Reasons to start ART 
promptly in seven communities 
(four Zambia, three South 
Africa)
Reasons to start ART 
Health services factors Positive perception and previous experience of health 
facility and services seen as facilitating care
Previous (affirmative) relationships with staff at facilities
Home testing, information, linkage to care and support 
from CHWs (including CHiPs)
Availability of adherence clubs
Preferential treatment due to their occupation or status 
(police, school students)
Key health motivations Illness: feeling sick, prolonged severe ill health
Co-infection, i.e. HIV & TB impacting on health
Previous HIV-related death in the household/family
Pregnancy (PMTCT)
ART viewed as way to maintain or regain physical health
Family responsibility: being well to take care of family
Keeping partner safe/negative (treatment as prevention)
Familial and social factors Relatives/spouses (including HIV + partners and family) 
facilitating treatment initiation
Families providing support: transport, social support, 
adherence support
Social networks as support structures: church, friends, 
loan groups
Friends collecting treatment on behalf of PLWH
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Past experiences did play a part in the decision to start 
treatment for some, even if they were not yet ill themselves. 
Seeing a family member grow weak and die because of HIV, 
and in some cases remembering episodes of ill health as a 
child, prompted access to treatment. A 21-year-old woman 
(Z2) commented:
I have experienced this, not myself but with my late 
mum when she defaulted, she then stopped taking her 
medication and this cost her so much such that she 
had meningitis and her kidney could not function, so I 
learned from her. So, I started, and I can’t stop because 
what happened to her can also happen to me.
Discussion
Over the first 2 years of delivering the HPTN 071 (PopART) 
intervention we observed steep reductions in the time taken 
from community household HIV testing to linking to care 
and starting ART. However, ~ 30% of individuals had not 
initiated ART by 12 months after testing.
Whilst immediate ART for all PLHIV and “same day 
ART start” have been shown to enhance health outcomes 
[48] when delivered at the clinic, and is being advocated 
as a clinic-based approach to facilitate ART-start in HIV 
programmes [49], home-based and community wide pro-
grammes offering HIV testing require additional time to link 
to care and treatment in a clinic [50]. A meta-analysis has 
identified that the best way to reach coverage approaching 
the first UNAIDS 90% target is through community models 
of testing [51], an observation supported by more recent 
studies [15, 36, 52]. This approach, as well as HIV-self-
testing [53, 54], means there will still be a gap between the 
initial test result, confirmation of HIV-positive status and 
ART initiation. Therefore, the current programmatic empha-
sis supported by policy makers and funders [55] on “same 
day test and start”, whilst potentially expediting the time 
required to initiate ART for those testing HIV-positive, may 
not be applicable to those testing within the community, 
unless community-based ART initiation is implemented 
[50].
The delay or loss of PLHIV to starting ART is a criti-
cal challenge to delivering a successful HIV treatment and 
prevention cascade. The reasons for this are multi-facto-
rial, as we describe above and highlighted in a previously 
reported nested case control study in HPTN 071 (PopART) 
[56]. Community engagement, mobilisation and messaging 
were an integral part of the HPTN 071 (PopART) trial and 
were refined over time (as described above) to encourage 
timely linkage to care. The CHiPs workers became more 
accepted and familiar within the communities and the health 
care facilities similarly became more comfortable offering 
universal ART, as we have described elsewhere [56]. Despite 
these enhancements, there were key groups of PLHIV that 
chose not to link to care or start ART, in keeping with find-
ings from other similar trials [12]. We found that in South 
Africa, men tended to link to care and initiate ART more 
slowly than women, as has been noted by other investigators 
[46, 47]). Yet, our data from Zambia which show that men, 
particularly older men, linked to care more quickly than 
women, runs counter to the large body of work highlighting 
men lagging behind in accessing care [57]. We observed that 
one reason for this difference in Zambia was because some 
women who linked to care faced negative repercussions from 
their partners, particularly younger and middle-aged women. 
It may also be that a successful campaign to encourage men 
to test and link to care in the context of also accessing care 
for other conditions, which was provided as part of the Pop-
ART community engagement activities in Zambia, increased 
uptake [42].
The fear of ‘being seen’ accessing treatment remains a 
threat, particularly for marginal and higher status groups. 
The stigmatising attitudes in communities are enacted 
through the concerns expressed by PLHIV about engage-
ment with the health system, resulting in fearing being seen 
and possible disclosure of their HIV-status. This risk of 
being identified, and associated stigma, was exacerbated by 
the way the clinics were usually organised (with separate 
areas for PLHIV to wait) which we describe elsewhere [40], 
and (in most but not all clinics) high numbers of clients, 
over-crowding, long waiting times and congestion [ibid]. 
These health system factors interact with stigma about HIV, 
increasing perceived barriers to care for some PLHIV. The 
concerns around stigma are a reflection of wider community 
level stigma about HIV in these communities [35]. In addi-
tion, experience with overstretched health services and busy 
workers means that PLHIV are aware that a commitment to 
life-long treatment involves routine and lengthy interactions 
with health care services and raises questions and fears for 
the sustainability of treatment.
Despite the encouraging shortening of time to ART ini-
tiation across the two Rounds reported in this paper there is 
still a substantial number who do not link to care within the 
first 12 months; there are differences between communities 
as well as household and individual reasons for delaying 
treatment, as we describe above. The significant differences 
across communities were related to degrees of mobility, 
presence of middle-class residents, employment options, 
and congestion at the government health facility. This cor-
responds with earlier mixed method analysis of first year 
intervention uptake in the four Zambian Arm A interven-
tion communities [56] and underscores the influence of the 
local context on the ability of PLHIV to link to care. Our 
analysis identified some groups (for example, younger men 
and mobile populations) as often being slower to start ART, 
AIDS and Behavior 
1 3
probably because the health service delivery mechanisms 
are not appropriate to their needs. These observations are in 
keeping with the findings from other studies [12, 16, 22, 28, 
58]. As has been demonstrated recently with the findings for 
the ANRS 12249 TasP Cluster-Randomised Trial, even in 
the controlled environment of a trial, ensuring prompt treat-
ment may be challenging [15].
Given health system constraints, as well as PLHIV deci-
sion-making, circumstances and stigma, barriers will continue 
to affect uptake. These barriers may be addressed to some 
extent by the current motivation for differentiated models of 
care, which aims to adapt health service provision to client 
needs through less frequent clinic attendance for people who 
are stable on ART, and providing non-facility based outlets for 
ART delivery closer to people’s homes [59, 60].
There is a recognised HIV continuum of care or “cascade” 
that requires at least three critical steps to ensure delivery of 
successful ART to all PLHIV. In the original care cascade [61, 
62], Stage 2 was retention in pre-ART care until the PLHIV 
became eligible for ART. Fox and Rosen [63] argue that Stage 
2, is now redundant because there should be no delay between 
diagnosis (Stage 1) and eligibility to start ART (Stage 3). Yet, 
as our findings show there remain significant gaps in the HIV 
care continuum, challenging ART coverage. While the reduc-
tion in Stage 2 is logical for those testing within a health care 
facility, a brief `pre-ART’ period may serve as an opportunity 
to come to terms with HIV status prior to commencing ART 
[64]. This time, in particular for asymptomatic PLHIV, may 
serve an important role. Indeed, in the longer-term, immedi-
ate same day ART may need to be complemented with other 
options, to ensure the sustainability of the approach. While 
shortening the gap between testing and treatment is clinically 
important, it is an imperative that support for people for their 
treatment decision-making, and facilitating access to care, is 
provided.
Our findings show that PLHIV often delayed starting ART 
because of issues to do with the quality of care available and 
the stigma associated with accessing care. If the quality of 
and access to care were to improve (including re-arranging 
service access to integrate HIV with other care) and stigma 
were to reduce, fewer people may delay starting treatment. 
That said, there may remain individuals who require some 
time to come to terms with the challenges of living with HIV 
prior to starting therapy, a finding corroborated in other set-
tings [34, 65–68], although in the PopART study, because of 
the home-based testing model, same day ART start was not an 
option. Despite the multiple operational challenges to deliver 
optimal treatment and care for all PLHIV in resource limited 
high burden settings, more work is needed on changing mes-
saging, stigmatising attitudes towards PLHIV and capacity at 
health care facilities. Respect for individual choice means that 
a differentiated model of care [69, 70], with multiple options, 
might be the best way to deliver the breadth of ART coverage 
necessary to retain all PLHIV in care and get to zero new 
infections and zero deaths from HIV-related illness.
Conclusion
To enhance ART coverage amongst all PLHIV, timely link-
age to care is necessary. However, for programmes offer-
ing community-based HIV-testing, unless community ART 
initiation is offered, there is an inevitable lag between HIV 
testing and ART initiation. Our findings suggest that for 
some PLHIV a period of adjustment maybe important for 
the individual newly-diagnosed and sometimes also for their 
family. We need to work on interventions that ensure clear 
messaging about the benefits or ART, that limit stigma, 
structural barriers, overcrowding and long waiting times, 
where they exist. And we need to promote prompt treatment 
whilst allowing people, if necessary, to take time to adjust 
and think, without compromising their health outcomes. The 
time and support needed may be different for women and 
men, in different local contexts and for people of different 
ages.
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